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Summary Forty-two families with two or more cases of testicular cancer have been reported to the UK
Register for Familial Testicular Cancer, comprising two pairs of identical twins, 27 sets of other brothers (25
pairs, two triples), nine father-son pairs, two pairs of first cousins and two uncle-nephew pairs. In total 91
testicular tumours are described in 86 individuals (42 (46%) pure seminoma, 49 (54%) other germ cell
tumours). The median age at diagnosis in these patients was significantly younger than that in a comparable
series of non-familial patients (29 c.f. 32.5 years, P<0.01). In a case-control comparison of 794 testicular
cancer patients, eight patients (1.0%) had a brother and four patients (0.5%) had a father with a previous
diagnosis of testicular cancer at the time of their own diagnosis (and these families are all included in this
report). Two out of 794 controls (0.3%) had a first degree relative with testicular cancer. The cumulative risk
to a brother of a patient for developing testicular cancer by the age of 50 years was estimated to be 2.2%
(95% C.I. 0.6-3.8%) which results in a relative risk of 9.8 (95% C.I. 2.8-16.7) in comparison with the general
population. HLA Class I typing of 21 affected sib-pairs demonstrated four (19%) sharing two haplotypes, 13
pairs (62%) sharing one and four pairs (19%) sharing none. This did not differ significantly from the expected
proportions of 25%/50%/25%. It is unlikely, therefore, that there is a major gene associated with testicular
cancer predisposition within or closely linked to the major histocompatability gene complex on chromosome 6.
There are numerous reports in the literature offamilies where
two or more first degree relatives have been diagnosed with
germ cell tumours of the testis. To date at least 21 pairs of
identical twins, 82 sets of brothers (other than identical
twins) and 31 father-son pairs have been reported (Weissbach
& Widman, 1986; Dieckmann et al., 1987 and references
therein; Dieckmann & Keyserlingk, 1989 and references
therein; Goss & Bulbul, 1990; Patel et al., 1990). Only one
attempt has been made to estimate the risk of testicular
cancer in men who have an affected first degree relative.
Tollerud et al. (1985), using data derived from a study of 225
men with testicular cancer, calculated that having a first
degree relative with testicular cancer was associated with a
6-fold elevated risk in comparison with the general popula-
tion. There has been relatively little research into whether the
excess in familial cases occurs as a result of a genetic predis-
position, common environment or both (Gedde-Dahl et al.,
1985; Dieckmann et al., 1987; Forman, 1989; Oliver, 1990).
We have established a UK-based register for familial testi-
cular cancer to provide a means for the systematic documen-
tation of new cases, including histological verification, and
for obtaining standardised lymphocyte-DNA samples from
affected and unaffected family members for subsequent gene-
tic linkage analysis. In this paper we describe data on the
first 42 families reported to the register for which confirm-
ation of the diagnosis has been obtained.
A sub-set of these families were identified from interviews
about family history with men diagnosed as having testicular
cancer for whom an age-matched control was also inter-
viewed. Using these families, it was possible to estimate the
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risk of developing testicular cancer if a first-degree relative
had been previously affected.
There have been a number of studies (De Wolf et al., 1979;
Majsky, 1979; Pollack et al., 1982; Oliver et al., 1986a,b;
Dieckmann & Keyserlingk, 1988; Kratzik et al., 1989) which
show that patients with testicular cancer have a different
distribution of histocompatibility antigens (HLA) compared
with control populations. Because of this, it has been sug-
gested that disease susceptibility may be partly influenced by
a gene within, or closely linked to, the HLA complex on
chromosome 6 (Oliver et al., 1986a,b). We have, therefore,
conducted a sib-pair analysis (Haseman & Elston, 1972;
Thomson & Bodmer, 1976) for HLA haplotype association
on those families from whom appropriate blood samples
could be obtained. If there was a linked gene in the HLA
region, a much stronger association should be observed
within families than occurs when sporadic cases are typed
(Bodmer, 1982).
Methods
Case ascertainment
Familial cases of testicular cancer were mainly identified as a
result of a general mailing to consultants in oncology and
radiotherapy throughout the UK. Subsequent to the mailing,
further families were notified to the register on an ad-hoc
basis. Another source of cases arose from structured inter-
views with men participating in a national population-based
case-control study of testicular cancer (full details of which
will be published elsewhere). These men had been diagnosed
with testicular cancer between 1984 and 1986 and were aged
15 to 49 years at diagnosis. All men within this age range
who were resident in any of eight predefined geographical
areas (each within a different Regional Health Authority)
were eligible for entry into the study, with the exception of
those in non-white caucasian racial groups and those mental-
ly unable to participate in an interview. In total 863 men
were eligible for entry, of whom 794 (92%) completed an
interview. One part of the interview was concerned with
Br. J. Cancer (1992), 65, 255-262 '." Macmillan Press Ltd., 1992256 D. FORMAN et al.
diagnosis of cancer in male relatives.
When a potential testicular cancer family had been identi-
fied, full details were recorded about the cases and a family
pedigree was constructed. Usually this process involved inter-
views with the cases and with other family members.
Confirmation of the diagnosis in all suspected cases was
accomplished by obtaining copies of histopathology reports
from the hospitals where treatment took place. As it was not
intended, because of small numbers, to look at histological
sub-types of testicular cancer in fine detail, a secondary
review of pathology was not undertaken. In a few cases, full
histopathology reports were unavailable and in these in-
stances supplementary clinical details were obtained to con-
firm the diagnoses. Having established the diagnosis and
obtained other relevant details, efforts were then made to
obtain blood samples from the affected family members and
then from other informative relatives in the pedigree.
Relative risk estimation
The prevalence of testicular cancer among first-degree rela-
tives (i.e. fathers and brothers) of the 794 cases participating
in the case-control study was used to estimate the size of
familial risk. An initial comparison was made with the preva-
lence of testicular cancer among the 794 control men
interviewed in the same study. These men were selected at
random from the list of the general practitioner with whom
the case was registered and were matched ( ±1 year) for age.
Any reports of relatives with testicular cancer were followed
up and had to be confirmed by a histopathology report in
order to be included in the comparison. A matched case-
control analysis (Breslow & Day, 1980) to estimate relative
risk was then carried out. Case-control analysis is, however,
extremely imprecise. This is partly because of the small
number of affected relatives, especially in the control group
(see Results), and partly because it does not fully take
account of the number of brothers at risk or the length of
time for which they are at risk. An additional estimate of the
risk to brothers was, therefore, obtained by actuarial anaylsis
(Peto et al., 1976). Person years were calculated for all
brothers of cases from their birth to the date of interview of
the case or to prior death of the brother. This then enabled
the calculation of a cumulative risk for a brother developing
testicular cancer by a given age. This risk was then compared
with the equivalent population risk calculated from England
and Wales National Cancer Registration Scheme data for the
year 1985 (OPCS, 1990).
Bloodpreparation and HLA typing
Blood (25 ml) was taken into bottles containing 0.33% Tri-
sodium Citrate and 0.5AM Mercaptoethanol, in RPMI 1640
Hepes buffered medium. Lymphocytes for HLA typing were
prepared by centrifugation over a Lymphoprep (Nyegaard)
density gradient, and HLA typed according to the method of
Bodmer and Bodmer (1979), using a panel of locally avail-
able antisera.
Haplotypes were assigned by HLA typing of parents and
sibs and looking at the patterns of antigen inheritance. This
allowed for the determination of haplotype sharing between
affected sibs. In some cases it was not possible to estimate
unambiguously the number of shared haplotypes because
either one parent was homozygous or one parent was not
tested and could potentially have been homozygous. The
observed distribution of haplotype sharing was compared
with that expected on the basis of mendelian segregation and
tested with a chi-square statistic (Thomson & Bodmer, 1976).
Where there was ambiguity about the number of shared
haplotypes an assumption of maximum sharing was made
solely for the purposes of this analysis. One sibship, for
which the HLA typing has been reported previously (and
partly gave rise to the hypothesis under consideration), was
excluded from the initial analysis.
Reported identical twins were checked for monozygosity
by southern blotting with mini-satellite probes (R. Hawkins,
personal communication.
Results
Description offamilies
In total, 42 families with two or more members diagnosed
with testicular cancer had been reported to us or identified by
us by March 1991. Details of the cases in these families are
listed in Table I. Three of these families (nos. 10, 39, 42) have
been previously reported (Oliver et al., 1986b). Table I shows,
for each case, the age at diagnosis, the side and histological
classification of the tumour and whether or not the patient
had a history of undescended testis (UDT). Twelve families
that were identified through the national case-control study,
and were used in the risk estimates, are also indicated.
In TableI, there are two pairs of identical twins, 27 sets of
other brothers (including one pair of half brothers), nine
father-son pairs, two pairs of first cousins and two uncle-
nephew pairs. There are four families where one brother of a
pair has had bilateral testicular cancer (family nos. 1, 2, 19,
20) and there is one such father (family no. 31). There are
also two sibships of three affected brothers (family nos. 7,
10).
There are 91 tumours described in Table I present in 86
individuals in the 42 families, five patients having had bila-
teral disease. Of the 91 tumours, 42 have been categorised by
local pathologists as pure seminoma, two as teratoma differ-
entiated, 20 as malignant teratoma intermediate, 16 as malig-
nant teratoma undifferentiated, seven have combined semin-
oma and teratoma histologies and four could only be classified
as malignant teratoma without further specification. Alto-
gether, there were 45 right-sided and 41 left-sided tumours
and five unilateral tumours where the side was not recorded.
Table II summarises the histological classification into two
groups, pure seminoma and other germ cell tumours, for the
86 patients and shows the median age at diagnosis for each
group. For comparison purposes, similar data are presented
for the 781 patients in the case-control study without a
family history. The median age at initial diagnosis for the 86
familial cases was 29 years (range 16-51 years). For patients
with seminoma, the median age was 32.5 years (range 20-51
years), while for patients with other germ cell tumours it was
26 years (range 16-47 years).
The median age at diagnosis of the 781 non-familial
patients, who were all aged between 15 and 49 years, was
32.5 years overall and 35.5 and 28.5 years for patients with
seminoma and other germ cell tumours respectively. For both
histological categories, therefore, the median age at diagnosis
was younger in the familial patients. This difference was
statistically significant for those with seminoma and for all
histologies combined (P<0.05 and <0.01 respectively,
Mann-Whitney test).
The median age at diagnosis of the first tumour in the five
familial patients with bilateral cancer was 26.5 years (range
20-33 years) which was younger than in those with unila-
teral cancer (29.5 years) although the difference was not
statistically significant. Two of these five patients with an
initial seminoma were diagnosed at 32 and 33 years while
three with a teratoma were diagnosed at 20, 22 and 26 years.
In the father-son pairs, the median age at diagnosis in the
fathers (34.5 years) was significantly (P<0.01, Mann-Whit-
ney test) older than in the sons (24.5 years) with a mean
difference of 13.2 years (range 3-22 years). There were six
seminomas in the fathers compared to five in the sons. In the
non-twin brother pairs there was no tendency for the elder
brother to have a later age at diagnosis than the younger
brother and the mean difference in age at diagnosis between
all broth.rs (including twins) was 5.5 years (range 1-20
years).
Information about a prior history of UDT was available
for 79 individuals and, of these, eight (10.1%) had such a
diagnosis which was bilateral in three cases. In four of the
five unilateral cases the cancer was diagnosed in the ipsi-
lateral testis. In no family was there more than one case of
UDT. All the unilateral cases of UDT underwent orchido-FAMILIAL TESTICULAR CANCER
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Table II Number and median age at diagnosis of testicular cancer
familial cases on UK register and non-familial patients in national
case-control study by histological classification
Familial casesa Non-familial cases
Median age Median age
at diagnosis at diagnosis
Histology No. (G) (years) No. (o) (years) Pb
Pure 40 (46.5) 32.5 391 (50.0) 35.5 0.02
seminoma
Other germ 46 (53.5) 26 390 (50.0) 28.5 0.21
cell
All 86 29 781 32.5 0.007
Chi-square' = 0.39, 1 d.f., n.s.
aData refer to initial tumour for five bilateral cases. bMann-Whitney
test for comparison of median ages at diagnosis. cChi-square test to
compare distribution by histology.
pexy in childhood while none of the bilateral cases had a
corrective operation.
Table I documents reports of testicular cancer in other
family members, reports of cancer at other sites in first
degree family members, urogenital abnormalities in the cases
and other family members and other miscellaneous inform-
ation. The two reports of testicular cancer (a second cousin
in family no. 6 and an uncle in family no. 20) were confirmed
from histology but the reports of other cancers were based
solely on the information supplied by members of the family.
There were 15 such reports in other family members, seven in
mothers of cases (family nos. 3, 4, 13, 16, 19, 23, 40), six in
fathers (family nos., 3, 4, 6, 7, 26, 29), one in a sister (family
no. 13), and one in a second son of a father-son pair (fam,ily
no. 31). One father (family no. 7) had two primary cancers
and one case (family no. 39) developed a colon cancer after
his testicular tumour. A range of urogenital abnormalities
were reported in the cases and their relatives including
inguinal hernia, hydrocoele, and testicular torsion. The most
frequent was inguinal hernia which was reported in six of the
86 cases (7%), three (3.5%) being infantile.
Risk estimation
In the case-control study of 794 patients with testicular
cancer, one patient reported an identical twin with a previous
diagnosis of testicular cancer (family no. 2), seven patients
reported a non-twin brother with such a diagnosis (family
nos. 4, 5, 7 (two brothers), eight (twice), 9, 13, 23)* and four
patients reported a father (family nos. 30, 31, 34, 38). In
total, therefore, 12 out of the 794 patients (1.5%) reported a
first degree relative with a history of testicular cancer (exclud-
ing the first case in family no. 8).* There was one diagnosis
of testicular cancer among the fathers of the 794 controls and
one among the brothers i.e. two cases out of 794 (0.3%). All
these diagnoses were histologically confirmed. These figures
result in relative risks of 8.0 (95% C.I. 1.1-355.0) for deve-
loping testicular cancer if a brother has been previously
affected and 4.0 (95% C.I. 0.4-197.0) if a father has been
previously affected. Each testicular cancer case reported a
mean of 1.18 brothers and each control a mean of 1.26
brothers (12 and eight twin brothers, 923 and 995 non-twin
brothers reported by cases and controls respectively). Restric-
ting the case-control analysis to those cases and controls with
brothers did not substantively alter the relative risk.
Using actuarial analysis, the estimated cumulative risk for
brothers ofcases developing testicular cancer was 2.2% (95%
C.I. 0.6-3.8%) by the age of 50 years. This compares with a
risk of 0.23% based on 1985 England and Wales cancer
registrations and results in a relative risk of 9.8 (95% C.I.
2.8- 16.7).
HLA haplotype analysis
The HLA haplotype analysis for the 26 families where blood
samples were taken is shown in Table III. A comparison of
the extent of haplotype sharing with that expected as a result
of random mendelian segregation was carried out for the 21
sib-pairs that have not been previously reported. Assuming
maximum sharing of haplotypes in those families which
could not be unambiguously characterised, there were four
pairs of brothers where both haplotypes were shared, 13
pairs where one was shared, and four pairs where no haplo7
types were shared. Compared to an expected distribution of
25%:50%: 25% the resulting chi-square statistic (1.19) was
non-significant. HLA haplotypes for the two cousin pairs and
the two uncle-nephew pairs are also shown in Table III, two
of these families having been reported previously (Oliver et
al., 1986b). Uncle-nephews have a 50% probability and
cousins have a 25% probability of sharing one haplotype.
Both uncle-nephew pairs and one of the cousin pairs share
one haplotype. Because of the small numbers of these second
degree families they could not be combined into a summary
statistical analysis.
Discussion
The families reported here add substantially to the literature
increasing the total number of reports of familial cases by
about 30%. Our best estimate of the proportion of cases that
are familial, derived from the case-control study, is 1.5%
which is similar to other recent estimates (Tollerud et al.,
1985; Dieckmann et al., 1987). This would indicate that most
familial cases are not reported in the literature and that each
year there should be about 15 such cases in the UK and 90 in
the USA alone (assuming 1,000 and 6,000 new diagnoses per
annum in the UK and USA respectively (Cancer Research
Campaign, 1990; American Cancer Society, 1990).
As with other forms of cancer (Anderson, 1975), familial
cases were diagnosed at younger ages than non-familial cases.
The non-familial cases from the case-control study were an
appropriate group to use for these comparisons because
similar standards of histological review were adopted. The
case-control study did not, however, recruit cases over the
age of 49 years and, as approximately 14% of testicular
cancers are diagnosed after this age (OPCS, 1990), differences
between familial and non-familial cases in age at diagnosis
are likely to be greater than those reported. Indeed the 13
familial cases from the case-control study had a median age
at diagnosis of 28.5 years (28.5 years for nine cases with
seminoma and 24 years for four cases with other germ cell
tumours) i.e. for each category slightly younger, although not
significantly so, than the median age for all familial cases
presented in Table II.
The difference in age at diagnosis between familial and
non-familial cases is unlikely to be due to increased surveil-
lance of families after the first cases had been identified. The
median age at diagnosis of the first diagnosed members (who
would be free of any surveillance bias) of the 42 families was
26.5 years overall (30.5 years for 17 cases with seminoma and
25.5 years for 25 cases with other germ cell tumours) i.e. not
substantially different from the medians of all family cases
presented in Table II.
There was a substantial difference in age of diagnosis
between fathers and sons among the nine pairs in this study
and this could indicate 'genetic anticipation' as suggested by
Raghavan et al. (1980) ie, the earlier appearance of a genetic
condition with increased severity in successive generations. It
is, however, likely that selection due to death or infertility of
young cases in the paternal generation before they could
produce children, could entirely explain this difference.
The presence of bilateral tumours in five of the 86 individ-
*In family no. 7, the proband reported two affected brothers while in
family no. 8 both affected brothers were included in the case-control
study and, thus, reported each other. In the case-control com-
parisons the first case from family no. 8 was omitted from the
analysis as, at diagnosis, he was not a familial case.260 D. FORMAN et al.
Table III A HLA haplotypesa for 22 (non-identical twin) sets of
brothers with testicular cancer
Family Case 1 Number of
no. (from (Older brother) Case 2 haplotypes
Table I) A C B A C B sharedb
3 29 - 44 31 wlO w6O 1
2
4 2
3
5 1
2
6 1
32
7 2
3
8 1
24
9 1
1
w6 w57
- 7
- 7
- 38
w2 27
w3 w62
w5 44
- 8
wI 51
- 8
_ 18
w6 w57
w6 w57
lOC 29 7
32 w2 27
(3)
11 1
26
12 1
2
13 31
31
14 2
3
15 2
29
16 1
2
17 26
29
18 24
32
19 2
2
20 3
3
21 3
w68
26 2
3
27 29
w68
29 25
w7 8
- 38
w7 8
- 44
w2 27
w3 w60
wlO w60
- 51
w9 w62
- 44
w7 8
wlO w62
w4 35
- 44
39
- 44
w7 7
w6 13
wl 51
- 44
w7 7
w7 44
wI w22
w7 7
- 44
w2 27
- 44
2 w6
2 or 3 -
2 or 3 w4
29 wlO
31 wlO
1 w3
2 w3
(3)1 -
2 -
1 w7
2 w6
1 w6
2 -
(2) 2
32
(3) 2
32
26
30
31
26
2
3
2
w68
2
3
26
29
11
26
2
3
3
26
3
w68
3
2
w68
25
w2
w2
w7
w7
w6
w2
w6
wlO
w9
w4
w5
w7
w4
wlO
w7
w7
w8
w7
w7
w6
w7
w4
w2
w57
7
35
w62
w60
w62
w62
51
8
8
37
w57
8
13
27
13
27
8
38
8
13
27
13
w60
51
w62
w53
44
7
35
44
51
w60
7
7
44
w64
7
44
w57
7
35
27
44
I
0
0
1 & 2 =1
I &3=1
2 & 3 = 2
1 or 2
0 or 1
2
0 or 1
0
2
0
0 or 1
0 or 1
2
0 or 1
2 wlO w60 33 - 18
B HLA haplotypes for two sets of first cousins and two sets of
uncle-nephews with testicular cancer
Case I Number of
Family no. (Older cousin/uncle) Case 2 haplotypes
A C B A C B sharedb
39c (cousins) 3 44 3 w6 w57 0
30 w4 35 w68 w7 44
40 (cousins) 11 - 44 3 w2 27 1
w68 w7 7 w68 w7 7
41 (uncle/ 2 w9 w55 2 w9 w62 I
nephew) w68 w4 w53 w68 w4 w53
42c(uncle/ 1 w7 8 1 w7 8 0 or I
nephew) 2 7 1 w7 8
Table III (cont'd)
C Sib-pair analysis for 21 pairs of non-identical twin brothers
No. haplotypes
shared Observed Expected
0 4 5.25
1 13 10.5 x2= 1.19, 2d.f., n.s.
2 4 5.25
aA 'w' prefix is conventionally assigned to antigens which are not yet
fullydefined. Cwantigensareoften notserologicallydetectable andlack
ofa Cwcharacterisationdoes notindicateantigenabsence.bAssessment
of the number of shared haplotypes was based on the HLA class I
characterisation of the affected cases and of other family members
(results for the latter not shown). For seven families (nos 11, 12, 15, 19,
20, 26, 42), it was not possible to assess unambiguously the degree of
haplotype sharing because parental homozygosity (two copies of the
sameantigens) could notbeexcludedand anapparent sharedhaplotype
in the affecteds could have been inherited from different parental
chromosomes. In onefamily(no.41)theAw68 Cw4Bw 53haplotypeis
so rare that sharing could be assumed despite the absence ofparental
material.cFamily HLA typing reported previously (Oliver etal., 1986b)
(family no 39 now differs from original report of the haplotype)
uals (6.0%) was higher than expected from unselected case
series where the prevalence is in the order of 2.5% (Dieck-
mann et al., 1986). This is analogous to the situation in other
paired organs e.g. breast, eye, kidney, in which bilateral
disease is more common in familial cases. According to the
model for retinoblastoma as proposed by Knudson (1986),
this would be compatible with the occurrence of a germ line
mutation in those familial cases which have a genetic predis-
position. The bilateral cases did have an earlier age at onset
of disease although this comparison, based on only five
patients with bilateral disease, was not statistically significant.
The prevalence of UDT in these familial cases (10%) was
no different from that recorded in other case series where the
prevalence is usually between 8 and 10% (Chilvers & Pike,
1989). Thus although UDT is a major risk factor for testicu-
lar cancer (Chilvers & Pike, 1989), there is no evidence from
these data that it has a stronger association with familial
forms of the disease. Similarly a history of infantile inguinal
hernia did not seem to be more common in these familial
cases compared with non-familial cases (Swerdlow et al.,
1987). It was not possible to estimate whether other urogeni-
tal abnormalities in the affected cases or their relatives were
specifically associated with familial testicular cancer as has
been reported previously (Tollerud et al., 1985). There were,
however, specific families with a remarkably high prevalence
of such abnormalities in combination with familial cancer.
An example is family number 10 where there were three
brothers with testicular cancer, a fourth who was hypogona-
dol and a fifth who was infertile.
Our risk estimate for the likelihood of developing testicular
cancer if a brother had already been affected was 8.0 in
comparison with a matched control group and, using actua-
rial methods, 9.8 in comparison with national registration
rates. The precision of the latter estimate was considerably
greater, reflected in the much narrower confidence intervals,
and the analysis on which it was based adequately takes into
account the period of time for which each brother was at
risk, the case with two affected brothers (family no. 7) and
the double-ascertained family (no. 8). A case-control com-
parison could also be biased in that controls may be less
likely to know about or to remember cancer diagnoses in
their brothers. A problem with using cancer registration rates
for comparison of the actuarial risk is that there may be
some routine under-reporting to cancer registries (Swerdlow,
1986). For this reason we only made use of the latest avail-
able rates (for 1985) rather than earlier years for which
under-reporting would be more extensive. Also, under-report-
ing is likely to occur less frequently in young and middle-
aged men with testicular cancer who are of intense clinical
interest. For these reasons, we believe that the extent of
under-reporting would be no more than 10%. Under-report-
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ing will be partly offset by the fact that secular rates of
testicular cancer have been increasing (Forman, 1989) and
thus 1985 rates will overestimate the risk at earlier time
periods. In summary, therefore, we believe that our figure of
a 9 to 10-fold risk to brothers is likely to be a reliable
estimate.
Although a similar actuarial risk for father-son families
could have been calculated, we did not believe that the
estimate obtained would have been reliable or particularly
meaningful. For most fathers the calendar periods at greatest
risk would have been prior to 1950 for which there are no
registration data available and for which 1985 data, as used
for the brothers, would be inappropriate. The case-control
comparison does indicate a 4-fold elevated risk of testicular
cancer to men whose fathers have had the disease. Tollerud
et al. (1985) calculated a 6-fold risk of-testicular cancer if
either a brother or a father has been previously diagnosed.
Our equivalent estimate from the case-control analysis, after
omitting the first case in family no. 8, was also 6.0 (95% C.I.
1.3-55.2) and is, therefore, identical.
It may be noted that the familial risk to brothers, even if
out by as much as 100%, is greater than that for most other
cancers (for which the risk is rarely greater than 4-fold)
(Easton & Peto, 1990) and similar to that for a history of
UDT (for which the risk is about 5-fold (Chilvers & Pike,
1989)). A small minority of cases seem, therefore, to have a
substantially elevated familial risk. This would suggest that
there could be a case for counselling first degree relatives of
affected cases about testicular self-examination. Any addi-
tional testicular problems in relatives, e.g. infertility or
atrophy, may be indications for further investigations such as
semen cytology and/or testicular biopsy. It should be empha-
sised that only about one in 50 brothers will be diagnosed
with testicular cancer and thus the absolute risk to brothers
is still quite small.
Having established a strong familial association, the ques-
tion arises of the extent to which this is a result of genetic
susceptibility. The marked racial differences in the incidence
of testicular cancer (Forman, 1989), the lack of change in
incidence in migrant groups (Muir et al., 1987) and the high
risk of testicular cancer associated with certain congenital
disorders of sexual differentiation (Verp & Simpson, 1987;
Savage & Lowe, 1990) all lend support to the possibility of a
genetic component.
There have been several HLA phenotyping studies of unse-
lected patients with testicular cancer (De Wolf et al., 1979;
Majsky, 1979; Pollack et al., 1982; Oliver et al., 1986a;
Dieckmann & Keyserlingk, 1988; Kratzick et al., 1989) and,
although not entirely consistent in their results, they have
hinted at an association between cancer risk and specific
antigens brought about by genetic disequilibrium. This assoc-
iation would indicate a linkage between a candidate predis-
position gene and the HLA complex on chromosome 6.
Anecdotal reports (Pollack et al., 1982; Tollerud et al., 1985;
Kandel et al., 1988; Hayakawa et aL., 1986; Oliver et al.,
1986b; Natsume et al., 1989; Dieckmann & Keyserlingk,
1989) of a higher than expected level of HLA haplotype
sharing between affected familial cases lend support to this
hypothesis.
The sib-pair analysis (Haseman & Elston, 1972; Thomson
& Bodmer, 1976) is a powerful tool to investigate genetic
linkage in this type of situation where extensive pedigrees are
not available. The method has been used successfully in
studies of a similar size to this one to look at the association
between HLA and both Hodgkin's disease (Hors et al., 1984)
and nasopharyngeal carcinoma (Lu et al., 1990).
Our analysis, based on 21 sib-pairs, shows that the level of
association with testicular cancer was no higher than that
expected by random segregation. This was so despite the
assumption of maximum possible sharing in families where
there was ambiguity about the number of haplotypes shared.
Combining the 21 pairs with the ten reported previously in
the literature resulted in four, 21 and six pairs sharing 0, 1
and 2 haplotypes compared with expected numbers of 7.75,
15.5 and 7.75 for which the chi-square (4.16) is non-signi-
ficant. The lack of association in our 21 pairs remained after
sub-dividing sib-pairs into different histological categories,
i.e., sib-pairs with only seminoma or only other germ cell
tumour histologies. There was also no difference in either
histological type or age at disease onset between those sib-
pairs that shared two haplotypes and those that shared one
or none. It is, therefore, unlikely that there is a major gene
associated with testicular cancer predisposition within or
linked to the major histocompatability complex. However as
class II typing has not been performed we cannot formally
exclude an association with class II loci that is not detectable
by linkage to class I loci, similar to the situation in Hodg-
kin's disease (Bodmer et al., 1989). In addition there remains
the possibility that HLA type might have prognostic signifi-
cance once the disease has developed (Oliver et al., 1986a).
We are currently investigating linkage with loci on other
chromosomes.
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